Polymer Lung Surfactants.

Animal-derived lung surfactants annually save 40 000 infants with neonatal respiratory distress syndrome (NRDS) in the United States. Lung surfactants have further potential for treating about 190 000 adult patients with acute respiratory distress syndrome (ARDS) each year. To this end, the properties of current therapeutics need to be modified.

Air-Water Interfacial Properties of Chloroform-Spread versus Water-Spread Poly((d,l-lactic acid- co-glycolic acid)- block-ethylene glycol) (PLGA-PEG) Polymers.

Polymers at fluid interfaces are used for a number of applications that include coatings, electronics, separation, energy, cosmetics, and medicines. Here, we present a study on an amphiphilic block copolymer, poly((d,l-lactic acid- co-glycolic acid)- block-ethylene glycol) (PLGA-PEG), at the air-water interface. PLGA-PEG at the air-water interface prepared by using an organic spreading solvent exhibits an extremely high surface pressure without the occurrence of desorption, making it an attractive candidate for a variety of uses in the areas mentioned above.

Effects of nanoparticles on the mechanical functioning of the lung.

Nanotechnology is a rapidly expanding field that has very promising applications that will improve industry, medicine, and consumer products. However, despite the growing widespread use of engineered nanoparticles in these areas, very little has been done to assess the potential health risks they may pose to high-risk areas of the body, particularly the lungs. In this review we first briefly discuss the structure of the lungs and establish that the pulmonary surfactant (PS), given its vulnerability and huge contribution to healthy lung function, is a mechanism of great concern when evaluating potential nanoparticle interactions within the lung.

Nonsurgical home treatment of middle ear effusion and associated hearing loss in children. Part II: Validation study.

In this prospective follow-up investigation, we examined the efficacy of a modified Politzer device in the home treatment of persistent middle ear effusion (MEE) and associated hearing loss in children who had previously participated in a similar clinical trial. Our study group was made up of 38 patients who had been either (1) untreated control participants in the previous study whose hearing in one or both ears had not returned to normal within 11 weeks of their initial audiologic pretest ("former control group"; n = 30), or (2) active-treatment participants in the previous study whose hearing sensitivity in at least one ear had not improved to within normal limits after treatment and who elected to undergo a continuation of treatment ("extended-treatment group"; n = 8). Treatment efficacy was determined by comparing differences in pre- and posttreatment air-conduction thresholds and otoscopic findings.

Nonsurgical home treatment of middle ear effusion and associated hearing loss in children. Part I: clinical trial.

We conducted a randomized, controlled clinical trial to investigate the efficacy of treatment of persistent middle ear effusion (MEE) and associated hearing loss with a modified Politzer device used in the home setting over a 7-week period. Efficacy was determined by comparing pre-and posttherapy air-conduction thresholds, tympanometric peak pressures, and otoscopic findings. The study group was made up of 94 children (174 ears), aged 4 to 11 years, who had at least a 2-month history of MEE and associated hearing loss.